Document Detail


Radiotherapy Improves Survival in Unresected Stage I-III Bronchoalveolar Carcinoma.
MedLine Citation:
PMID:  22420965     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
PURPOSE: To test the hypothesis that radiotherapy (RT) improves the outcome of patients with unresected, nonmetastatic bronchoalveolar carcinoma (BAC) by performing a population-based analysis within the Surveillance, Epidemiology, and End Results (SEER) registry. METHODS AND MATERIALS: Inclusion criteria were as follows: patients diagnosed with BAC, Stage I-III, between 2001 and 2007. Exclusion criteria included unknown stage, unknown primary treatment modality, Stage IV disease, and those diagnosed at autopsy. Demographic data, treatment details, and overall survival were retrieved from the SEER database. Survival was analyzed using the Kaplan-Meier method and log-rank test. RESULTS: A total of 6933 patients with Stage I-III BAC were included in the analysis. The median age at diagnosis was 70 years (range, 10-101 years). The majority of patients were diagnosed with Stage I (74.4%); 968 patients (14%) did not undergo surgical resection. Unresected patients were more likely to be older (p < 0.0001), male (p = 0.001), black (p < 0.0001), and Stage III (p < 0.0001). Within the cohort of unresected patients, 300 (31%) were treated with RT. The estimated 2-year overall survival for patients with unresected, nonmetastatic BAC was 58%, 44%, and 27% in Stage I, II, and III, respectively. Factors associated with improved survival included female sex, earlier stage at diagnosis, and use of RT. Median survival in those not receiving RT vs. receiving RT was as follows: Stage I, 28 months vs. 33 months (n = 364, p = 0.06); Stage II, 18 months vs. not reached (n = 31, nonsignificant); Stage III, 10 months vs. 17 months (n = 517, p < 0.003). CONCLUSIONS: The use of RT is associated with improved prognosis in unresected Stage I-III BAC. Less than a third of patients who could have potentially benefited from RT received it, suggesting that the medical specialists involved in the care of these patients underappreciate the importance of RT.
Authors:
Damien Urban; Mark Mishra; Amir Onn; Adam P Dicker; Zvi Symon; M Raphael Pfeffer; Yaacov Richard Lawrence
Related Documents :
20510635 - Feline injection-site sarcoma: past, present and future perspectives.
22566305 - Dietetic management in gastrointestinal complications from antimalignant chemotherapy.
22350955 - Impact of body mass index in korean patients with renal cell carcinoma.
22508825 - Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction ...
22327135 - Allo-sct for aml and mds with treosulfan compared with bu-based regimens: reduced toxic...
16670635 - Peripheral hemophagocytosis: an early indicator of advanced systemic inflammatory respo...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-3-13
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  -     ISSN:  1879-355X     ISO Abbreviation:  -     Publication Date:  2012 Mar 
Date Detail:
Created Date:  2012-3-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Department of Oncology, Sheba Medical Center, Ramat Gan, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Changes in pulmonary function after three-dimensional conformal radiotherapy, intensity-modulated ra...
Next Document:  A novel Peptide to treat oral mucositis blocks endothelial and epithelial cell apoptosis.